Novartis Korea Launches Domestic Phase 3 Clinical Trial of Aliskiren
According to Novartis Korea, Aliskiren (SPP100) is the first orally active ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.